On Friday, H.C. Wainwright maintained a Buy rating on shares of Vor Biopharma Inc. (NASDAQ:VOR) with a price target of $17.50, following the company's latest clinical study results. Vor Biopharma reported additional data from its Phase 1/2 VBP101 study on September 5. The study is focused on evaluating trem-cel (VOR33) followed by Mylotarg in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML).
As of the July 19 data cut-off, 18 patients had been treated with trem-cel, and 10 of these patients went on to receive Mylotarg. The doses of Mylotarg varied, with three patients receiving 0.5mg/m2, four patients receiving 1.0mg/m2, and three patients receiving 2.0mg/m2. The report highlighted that the treatment was well tolerated, and the drug exposure level was below the toxic threshold.
Moreover, all ten patients treated with Mylotarg achieved primary neutrophil engraftment with a median time of 9 days and platelet recovery in an average of 16.5 days. These results suggest a positive outcome for patients who received the combination treatment in the study.
The firm's analyst commented on the results, emphasizing the study's findings and the well-tolerated nature of the treatment. The analyst's reiteration of the Buy rating and the 12-month price target of $17.50 per diluted share reflects confidence in the stock's potential. This price target is based on the promising data from the ongoing clinical trial and the treatment's safety profile.
In other recent news, Vor Biopharma Inc. reported promising clinical data from its Phase 1/2 VBP101 study, indicating a positive safety profile and clinical efficacy for its treatment candidate, trem-cel. Baird reaffirmed its Outperform rating on Vor Biopharma, emphasizing the potential importance of relapse-free survival (RFS) durability in patients receiving higher doses of Mylotarg.
The firm also highlighted encouraging preliminary pharmacokinetic data for VCAR33ALLO, another pipeline product, and Vor Biopharma's intention to advance a CD45 antibody-drug conjugate program.
These developments are part of the recent unfolding events at Vor Biopharma. The company also released data from its VBP101 study for patients with acute myeloid leukemia (AML), demonstrating reliable engraftment, protection from toxicity, and early indications of patient benefit. Progress was reported with VCAR33ALLO, another treatment option, and a new preclinical asset, VADC45, targeting a protein associated with various blood cancers, was announced.
However, Vor Biopharma has been notified of noncompliance with Nasdaq's minimum bid price rule, with a deadline until February 25, 2025, to elevate its share price above $1.00 for at least ten consecutive business days. The company's failure to meet this requirement could potentially result in its stock being delisted from Nasdaq. These recent developments highlight the challenges faced by biotech companies in maintaining compliance with stock exchange regulations while progressing with clinical trials to improve treatment outcomes.
InvestingPro Insights
As Vor Biopharma advances its clinical studies, it's essential to consider the company's financial health and market performance. InvestingPro data reveals a market capitalization of $56.43 million, indicating the size of the company in the biopharmaceutical industry. Despite the promising clinical results, Vor Biopharma has a negative P/E ratio of -0.48, reflecting the company's current lack of profitability. Moreover, the stock has experienced significant volatility, with a 1-year price total return of -69.1%, suggesting that investors have had a challenging year.
From an operational standpoint, Vor Biopharma holds more cash than debt on its balance sheet, which is a positive sign for its financial stability (InvestingPro Tip). However, the company is quickly burning through cash, which raises concerns about its long-term financial sustainability (InvestingPro Tip). Investors should note that the stock price often moves in the opposite direction of the market, indicating that it may not follow broader market trends (InvestingPro Tip).
For those interested in a deeper analysis, InvestingPro offers additional tips on Vor Biopharma, providing valuable insights for investors looking to make informed decisions. With a range of metrics and expert analysis, InvestingPro can offer a comprehensive view of the company's prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.